|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 36.17 USD | +1.69% |
|
+0.31% | -1.02% |
| 21/07 | Gentherm Wins FDA Clearance for ThermAffyx Safety System | MT |
| 21/07 | Gentherm Gets FDA Clearance for Patient-Safety System | DJ |
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Revenues | 104.62Cr | 120.47Cr | 146.91Cr | 145.61Cr | 149.86Cr | |||||
Total Revenues | 104.62Cr | 120.47Cr | 146.91Cr | 145.61Cr | 149.86Cr | |||||
Cost of Goods Sold, Total | 74Cr | 93Cr | 111.75Cr | 108.97Cr | 113.64Cr | |||||
Gross Profit | 30Cr | 27Cr | 35Cr | 37Cr | 36Cr | |||||
Selling General & Admin Expenses, Total | 11Cr | 13Cr | 16Cr | 16Cr | 16Cr | |||||
R&D Expenses | 7.52Cr | 8.57Cr | 9.44Cr | 8.87Cr | 9.48Cr | |||||
Other Operating Expenses, Total | 18Cr | 22Cr | 25Cr | 24Cr | 26Cr | |||||
Operating Income | 12Cr | 5.52Cr | 10Cr | 12Cr | 10Cr | |||||
Interest Expense, Total | -27.58L | -42.94L | -1.46Cr | -1.53Cr | -1.38Cr | |||||
Net Interest Expenses | -27.58L | -42.94L | -1.46Cr | -1.53Cr | -1.38Cr | |||||
Income (Loss) On Equity Invest. | - | - | - | - | -46.38L | |||||
Currency Exchange Gains (Loss) | 14.87L | -67.78L | -59.18L | 95.99L | -2.84Cr | |||||
Other Non Operating Income (Expenses) | 1L | 11.47L | -19.26L | 10L | -1T | |||||
EBT, Excl. Unusual Items | 12Cr | 4.53Cr | 7.92Cr | 12Cr | 5.71Cr | |||||
Restructuring Charges | -38.57L | -6L | -47.39L | -1.31Cr | -1.25Cr | |||||
Merger & Related Restructuring Charges | - | - | - | - | -66L | |||||
Impairment of Goodwill | - | - | -1.95Cr | - | - | |||||
Gain (Loss) On Sale Of Investments | - | - | - | - | - | |||||
Gain (Loss) On Sale Of Assets | - | - | - | - | -21.96L | |||||
Asset Writedown | - | -62.91L | - | -25.01L | - | |||||
Other Unusual Items | - | - | - | - | - | |||||
EBT, Incl. Unusual Items | 11Cr | 3.84Cr | 5.5Cr | 10Cr | 3.58Cr | |||||
Income Tax Expense | 2.04Cr | 1.39Cr | 1.46Cr | 3.73Cr | 1.76Cr | |||||
Earnings From Continuing Operations | 9.34Cr | 2.44Cr | 4.03Cr | 6.49Cr | 1.83Cr | |||||
Net Income to Company | 9.34Cr | 2.44Cr | 4.03Cr | 6.49Cr | 1.83Cr | |||||
Net Income - (IS) | 9.34Cr | 2.44Cr | 4.03Cr | 6.49Cr | 1.83Cr | |||||
Net Income to Common Incl Extra Items | 9.34Cr | 2.44Cr | 4.03Cr | 6.49Cr | 1.83Cr | |||||
Net Income to Common Excl. Extra Items | 9.34Cr | 2.44Cr | 4.03Cr | 6.49Cr | 1.83Cr | |||||
Per Share Items | ||||||||||
Net EPS - Basic | 2.82 | 0.74 | 1.23 | 2.08 | 0.6 | |||||
Basic EPS - Continuing Operations | 2.82 | 0.74 | 1.23 | 2.08 | 0.6 | |||||
Basic Weighted Average Shares Outstanding | 3.31Cr | 3.31Cr | 3.28Cr | 3.13Cr | 3.06Cr | |||||
Net EPS - Diluted | 2.79 | 0.73 | 1.22 | 2.06 | 0.59 | |||||
Diluted EPS - Continuing Operations | 2.79 | 0.73 | 1.22 | 2.06 | 0.59 | |||||
Diluted Weighted Average Shares Outstanding | 3.35Cr | 3.35Cr | 3.31Cr | 3.15Cr | 3.09Cr | |||||
Normalized Basic EPS | 2.22 | 0.85 | 1.51 | 2.35 | 1.17 | |||||
Normalized Diluted EPS | 2.2 | 0.85 | 1.5 | 2.34 | 1.15 | |||||
Supplemental Items | ||||||||||
EBITDA | 16Cr | 9.96Cr | 15Cr | 18Cr | 16Cr | |||||
EBITA | 13Cr | 6.43Cr | 11Cr | 13Cr | 11Cr | |||||
EBIT | 12Cr | 5.52Cr | 10Cr | 12Cr | 10Cr | |||||
EBITDAR | 17Cr | 11Cr | 16Cr | 19Cr | 18Cr | |||||
Effective Tax Rate - (Ratio) | 17.93 | 36.32 | 26.59 | 36.49 | 48.97 | |||||
Current Domestic Taxes | 21.78L | 36.56L | 39.24L | -5L | 12.88L | |||||
Current Foreign Taxes | 1.84Cr | 1.76Cr | 2.38Cr | 2.72Cr | 3.86Cr | |||||
Total Current Taxes | 2.06Cr | 2.13Cr | 2.77Cr | 2.67Cr | 3.99Cr | |||||
Deferred Domestic Taxes | -44.91L | -61.84L | -70.51L | -78.78L | -1.02Cr | |||||
Deferred Foreign Taxes | 43.41L | -11.38L | -60.21L | 1.85Cr | -1.22Cr | |||||
Total Deferred Taxes | -2L | -73.22L | -1.31Cr | 1.06Cr | -2.23Cr | |||||
Normalized Net Income | 7.36Cr | 2.83Cr | 4.95Cr | 7.37Cr | 3.57Cr | |||||
Interest on Long-Term Debt | - | - | 28T | 14T | 5T | |||||
Non-Cash Pension Expense | 2L | 2L | 2L | 2L | 2L | |||||
Supplemental Operating Expense Items | ||||||||||
Research And Development Expense From Footnotes | 9.18Cr | 11Cr | 13Cr | 12Cr | 13Cr | |||||
Net Rental Expense, Total | 1Cr | 98.13L | 1.23Cr | 1.44Cr | 1.77Cr | |||||
Imputed Operating Lease Interest Expense | 15.39L | 20.62L | 56.36L | 69.07L | 76.62L | |||||
Imputed Operating Lease Depreciation | 84.66L | 77.51L | 66.21L | 75.24L | 1.01Cr | |||||
Stock-Based Comp., SG&A Exp. (Total) | - | - | - | - | - | |||||
Stock-Based Comp., Other (Total) | 1.45Cr | 65.99L | 1.16Cr | 1.04Cr | 1.23Cr | |||||
Total Stock-Based Compensation | 1.45Cr | 65.99L | 1.16Cr | 1.04Cr | 1.23Cr |
- Stock Market
- Stocks
- THRM Stock
- Financials Gentherm Incorporated
- Income Statement
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















